Investors / Switzerland / FORTY51 Ventures
FORTY51 Ventures
Venture capital · Basel, Switzerland · Europe
FORTY51 Ventures is a biotech venture creator and early stage investor that builds and incubates biotech companies in Europe. It acts as the first institutional investor in these companies and supports founders hands-on.
Invests inHealthcare & Biotech
In its own wordsbiotechventure creationearly stagefirst-in-classdrug developmenteurope
Your fit with FORTY51 Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsFORTY51 Ventures lists 5 checked portfolio companies on its own site and is named in 3 funding rounds, 2 of them as lead. Its most frequent entry is Seed, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 80% of its companies are based in Switzerland. It invests most often alongside Broadview Ventures, Forbion and High-Tech Gründerfonds.
Counts come from funding rounds that name FORTY51 Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 50% |
| Series A | 50% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 1 |
| '25 | 2 | 1 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 4th | 5 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 73th | 50% of entries at pre-seed or seed |
| Evidence | 92th | 20% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Broadview Ventures | 1 |
| Forbion | 1 |
| High-Tech Gründerfonds | 1 |
| Norwest | 1 |
| Pivotal Life Sciences | 1 |
| Supermoon Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Broadview Ventures
Compare FORTY51 Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with FORTY51 Ventures| Date | Company | Stage |
|---|---|---|
| 9 Jun 2025 | Series A | |
| 13 Mar 2025 | Seed Led | |
| 13 May 2024 | Seed Led |
Round details for FORTY51 Ventures
Amounts, full round histories and every co-investor in FORTY51 Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
5 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Allegria Therapeutics aims to redefine the treatment of allergic and inflammatory diseases by targeting mast cells | Healthcare & Biotech | May 2024Seed · 2 rounds | Page + round | |
| Ferrosa Therapeutics is developing next-generation biologics to address anemia of inflammation, an underserved condition affecting millions of patients with chronic kidney disease, cancer, and autoimmune disorders. | Healthcare & Biotech | Portfolio page | ||
| Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| Mosanna is developing an easy-to-use nighttime nasal spray to help restore the body’s natural airway control | Healthcare & Biotech | Portfolio page | ||
| Mosanna Therapeutics is developing a nighttime nasal spray to help restore the body's natural airway control for obstructive sleep apnea treatment | Healthcare & Biotech | Jun 2025Series A | Funding round |
About this data
site last read 9 Nov 2026- Site
- forty51ventures.com
- Last read
- 9 Nov 2026
- Watching since
- 9 Nov 2026
- Rounds since
- 13 May 2024
- Companies checked
- 5
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get FORTY51 Ventures' profile as data
Pull FORTY51 Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/forty51ventures.com
# also
GET /v1/firms/forty51ventures.com/portfolio
GET /v1/firms/forty51ventures.com/coinvestors
GET /v1/firms/forty51ventures.com/news